公开(公告)号：US20240350456A1

公开(公告)日：2024-10-24

申请号：US18631821

申请日：2024-04-10

Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Inventor： Ronaldo P. Ferraris ,  Nan Gao ,  Wei Vivian Li

IPC: A61K31/4045 ,  A61K31/047 ,  A61K31/132 ,  A61K31/145 ,  A61K31/19 ,  A61K31/194 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/20 ,  A61K31/205 ,  A61K31/216 ,  A61K31/221 ,  A61K31/223 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/513 ,  A61K31/522 ,  A61K31/609 ,  A61K31/66 ,  A61K31/685 ,  A61K31/7012 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61P1/12 ,  C12Q1/6883 ,  G01N33/68

CPC classification number: A61K31/4045 ,  A61K31/047 ,  A61K31/132 ,  A61K31/145 ,  A61K31/19 ,  A61K31/194 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/20 ,  A61K31/205 ,  A61K31/216 ,  A61K31/221 ,  A61K31/223 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/513 ,  A61K31/522 ,  A61K31/609 ,  A61K31/66 ,  A61K31/685 ,  A61K31/7012 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61P1/12 ,  C12Q1/6883 ,  G01N33/6893 ,  C12Q2600/158 ,  G01N2800/06

Abstract: Compositions and methods useful for the diagnosis and treatment of leaky gut syndrome and IBD including Crohn's disease are disclosed.

公开(公告)号：US20240350444A1

公开(公告)日：2024-10-24

申请号：US18756068

申请日：2024-06-27

Applicant: VITAFLO INTERNATIONAL LTD

Inventor： Robin Simon Brooke Williams ,  Matthew Walker

IPC: A61K31/20 ,  A23L33/12 ,  A61K9/107 ,  A61K9/14 ,  A61K31/4412

CPC classification number: A61K31/20 ,  A23L33/12 ,  A61K9/107 ,  A61K9/14 ,  A61K31/4412

Abstract: Decanoic acid for use in treating epilepsy wherein the decanoic acid is used in combination with perampanel, or a pharmaceutically acceptable salt thereof, or wherein the decanoic acid is used in combination with an AMPA receptor inhibitor that binds to the same AMPA receptor site as perampanel.

公开(公告)号：US20240342181A1

公开(公告)日：2024-10-17

申请号：US18299416

申请日：2023-04-12

Applicant: Xygenyx Inc.

Inventor： Alexy Goldstein

IPC: A61K31/52 ,  A61K9/00 ,  A61K31/20 ,  A61K31/201 ,  A61K31/205

CPC classification number: A61K31/52 ,  A61K9/0053 ,  A61K31/20 ,  A61K31/201 ,  A61K31/205

Abstract: A method and compositions of treatment for improving metabolic performance using supplementation, comprising the step of applying a supplement formulation to a human subject via a selected administration route, the supplement formulation comprising therapeutically effective amounts of a plurality of medium-chain triglycerides, a plurality of amino acids, and zeatin. The plurality of medium-chain triglycerides may comprise caprylic acid, and the plurality of amino acids may comprise carnitine which may be provided in the form of L-carnitine fumarate.

公开(公告)号：US20240335492A1

公开(公告)日：2024-10-10

申请号：US18745081

申请日：2024-06-17

Applicant: MARY KAY INC.

Inventor： Tiffany FLORENCE

IPC: A61K36/28 ,  A61K8/34 ,  A61K8/36 ,  A61K8/49 ,  A61K8/63 ,  A61K8/9711 ,  A61K8/9728 ,  A61K8/9761 ,  A61K8/9767 ,  A61K8/9789 ,  A61K8/9794 ,  A61K9/00 ,  A61K9/107 ,  A61K31/047 ,  A61K31/20 ,  A61K31/401 ,  A61K36/31 ,  A61Q19/00

CPC classification number: A61K36/28 ,  A61K8/345 ,  A61K8/361 ,  A61K8/4913 ,  A61K8/63 ,  A61K8/9711 ,  A61K8/9728 ,  A61K8/9761 ,  A61K8/9767 ,  A61K8/9789 ,  A61K8/9794 ,  A61K9/0014 ,  A61K9/107 ,  A61K31/047 ,  A61K31/20 ,  A61K31/401 ,  A61K36/31 ,  A61Q19/007

Abstract: A topical skin composition is disclosed. The composition includes Echinacea purpurea extract, Silybum marianum extract, behenyl alcohol, bisabolol, shea butter, Carthamus tinctorius oil, cetyl alcohol, citric acid, Cocos nucifera oil, glycerin, Helianthus annuus seed oil, microcrystalline cellulose, sodium hyaluronate, and squalane.

公开(公告)号：US12097180B2

公开(公告)日：2024-09-24

申请号：US17027057

申请日：2020-09-21

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： John J. McGlone

IPC: A61K31/404 ,  A61K9/00 ,  A61K31/20 ,  A61P25/00 ,  A61P43/00

CPC classification number: A61K31/404 ,  A61K9/0056 ,  A61K31/20 ,  A61P25/00 ,  A61P43/00

Abstract: Provided herein are maternal neonatal pheromonal agents capable of reducing aggression and improving feeding behavior in a pig. Compositions comprising the pheromonal agents and methods of using the agents to reduce aggression and improve feeding behavior and weight gain in the pig are also provided.

公开(公告)号：US20240307337A1

公开(公告)日：2024-09-19

申请号：US18677055

申请日：2024-05-29

Applicant: Queen Mary University of London

Inventor： Madusha Peiris ,  Ashley Blackshaw

IPC: A61K31/20 ,  A61K31/01 ,  A61K31/192 ,  A61K36/55 ,  A61K45/00 ,  A61P3/00

CPC classification number: A61K31/20 ,  A61K31/01 ,  A61K31/192 ,  A61K36/55 ,  A61K45/00 ,  A61P3/00 ,  A61K45/05

Abstract: The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.

公开(公告)号：US12090131B2

公开(公告)日：2024-09-17

申请号：US17903372

申请日：2022-09-06

Applicant: UCL BUSINESS LTD

Inventor： Robin Simon Brooke Williams ,  Matthew Walker

IPC: A61K31/20

CPC classification number: A61K31/20

Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the γ carbon of R1, or of only single methyl groups at both the β and ω-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.

公开(公告)号：US20240216456A1

公开(公告)日：2024-07-04

申请号：US18599039

申请日：2024-03-07

Applicant: Nodari RIZUN

Inventor： Nodari RIZUN

IPC: A61K36/47 ,  A61K31/047 ,  A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/352 ,  A61K36/185 ,  A61K36/48 ,  A61K36/61 ,  A61K36/752 ,  A61K36/76 ,  A61K36/835

CPC classification number: A61K36/47 ,  A61K31/047 ,  A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/352 ,  A61K36/185 ,  A61K36/48 ,  A61K36/61 ,  A61K36/752 ,  A61K36/76 ,  A61K36/835

Abstract: Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

公开(公告)号：US20240165061A1

公开(公告)日：2024-05-23

申请号：US18430796

申请日：2024-02-02

Applicant: Olfactive Biosolutions, LLC

Inventor： Christopher Hanson ,  William Harries

IPC: A61K31/19 ,  A61K31/045 ,  A61K31/085 ,  A61K31/20

CPC classification number: A61K31/19 ,  A61K31/045 ,  A61K31/085 ,  A61K31/20

Abstract: Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate insulin secretion and suppress appetite by activating ectopic olfactory receptors. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes, and disorders, such as abnormal insulin secretion.

公开(公告)号：US20240148681A1

公开(公告)日：2024-05-09

申请号：US18326636

申请日：2023-05-31

Applicant: Esperion Therapeutics, Inc.

Inventor： Roger Schofield Newton ,  Noah Laban Rosenberg ,  Diane Elaine MacDougall

IPC: A61K31/20 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/47 ,  A61K31/505

CPC classification number: A61K31/20 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/47 ,  A61K31/505

Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.